Fig. 2From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trialVariation (D8 – D1) in biomarker values in each treatment armBack to article page